Connect Biopharma Holdings (CNTB) Share-based Compensation (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Share-based Compensation of $1.2 million for Q1 2026, up 30.75% sequentially from $917000.0 in Q4 2025, and up 27.28% YoY from $942000.0 in Q1 2025.
Connect Biopharma Holdings (CNTB) Share-based Compensation (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Share-based Compensation for 3 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Share-based Compensation rose 27.28% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 37.32% YoY) and the FY2025 annual result came in at $3.7 million, down 44.62% from the prior year.
- Share-based Compensation improved to $1.2 million in Q1 2026 per CNTB's latest filing, from $917000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.0 million in Q3 2024 and troughed at $916000.0 in Q3 2025.
- A 3-year average of $1.3 million and a median of $1.2 million in 2026 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation tumbled 54.7% in 2025, then increased 27.28% in 2026.
- Over 3 years, Share-based Compensation stood at $1.4 million in 2024, then plunged by 34.55% to $917000.0 in 2025, then jumped by 30.75% to $1.2 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.2 million, $917000.0, and $916000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | 1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Mn |
| Jun 30, 2026 | 1.26 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 917,000.00 |
| Dec 31, 2025 | 917,000.00 |
| Sep 30, 2025 | 916,000.00 |
| Sep 30, 2025 | 916,000.00 |
| Jun 30, 2025 | 951,000.00 |
| Jun 30, 2025 | 951,000.00 |
| Mar 31, 2025 | 942,000.00 |
| Mar 31, 2025 | 942,000.00 |
| Dec 31, 2024 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 2.02 Mn |
| Sep 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |